MX393908B - Proceso mejorado para la preparacion de compuestos anfifilicos de imidazolinio. - Google Patents
Proceso mejorado para la preparacion de compuestos anfifilicos de imidazolinio.Info
- Publication number
- MX393908B MX393908B MX2017014138A MX2017014138A MX393908B MX 393908 B MX393908 B MX 393908B MX 2017014138 A MX2017014138 A MX 2017014138A MX 2017014138 A MX2017014138 A MX 2017014138A MX 393908 B MX393908 B MX 393908B
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- compounds
- improved process
- dotim
- imidazolinium compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- UFQDKRWQSFLPQY-UHFFFAOYSA-N 4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound Cl.C1CN=CN1 UFQDKRWQSFLPQY-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000002699 waste material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/14—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención da a conocer, en forma general, procesos mejorados para la preparación de compuestos anfifílicos de imidazolinio, tales como cloruro de 1-[2-(9(Z)-octadecenoiloxi)etill]-2-(8(Z)-heptadecenil)-3-(2-hidroxietil)imidazolinio (DOTIM). En forma particular, la invención da a conocer procesos para la síntesis de dichos compuestos que evitan la utilización de reactivos tóxicos, poseen menor costo y generan menos desechos que los métodos convencionales. El DOTIM y los compuestos afines pueden formularse como liposomas catiónicos que son útiles para su utilización como vectores químicos para la administración de ácido nucleico en la terapia génica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156677P | 2015-05-04 | 2015-05-04 | |
| PCT/EP2016/059823 WO2016177693A1 (en) | 2015-05-04 | 2016-05-03 | Process for the preparation of amphiphilic imidazolinium compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017014138A MX2017014138A (es) | 2018-03-15 |
| MX393908B true MX393908B (es) | 2025-03-24 |
Family
ID=55910251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014138A MX393908B (es) | 2015-05-04 | 2016-05-03 | Proceso mejorado para la preparacion de compuestos anfifilicos de imidazolinio. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10479768B2 (es) |
| EP (1) | EP3292106B1 (es) |
| JP (1) | JP6843765B2 (es) |
| KR (1) | KR102667024B1 (es) |
| CN (1) | CN107801395B (es) |
| AR (1) | AR104524A1 (es) |
| AU (2) | AU2016256965A1 (es) |
| CA (1) | CA2984696C (es) |
| CL (1) | CL2017002775A1 (es) |
| CO (1) | CO2017011326A2 (es) |
| EC (1) | ECSP17073692A (es) |
| ES (1) | ES2901788T3 (es) |
| HK (1) | HK1252354A1 (es) |
| IL (1) | IL255344B (es) |
| MX (1) | MX393908B (es) |
| PE (1) | PE20181172A1 (es) |
| PL (1) | PL3292106T3 (es) |
| RU (1) | RU2753541C2 (es) |
| TW (1) | TWI714580B (es) |
| UA (1) | UA123265C2 (es) |
| UY (1) | UY36667A (es) |
| WO (1) | WO2016177693A1 (es) |
| ZA (1) | ZA201708190B (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705655A (en) * | 1992-12-17 | 1998-01-06 | Megabios Corporation | Amphiphilic nitrogen containing imidazolinium derivative compounds and uses |
| US5830878A (en) | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
| US6121457A (en) * | 1997-11-14 | 2000-09-19 | Megabios Corporation | Compositions and methods using novel substituted imidazolium lipids |
| GB0201165D0 (en) * | 2002-01-18 | 2002-03-06 | Unilever Plc | Azetidinium modidfied poymers and fabric treatment composition |
| US7786153B2 (en) | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
| US8044215B2 (en) * | 2009-04-29 | 2011-10-25 | Juvaris Biotherapeutics, Inc. | Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds |
-
2016
- 2016-05-03 KR KR1020177033508A patent/KR102667024B1/ko active Active
- 2016-05-03 MX MX2017014138A patent/MX393908B/es unknown
- 2016-05-03 TW TW105113727A patent/TWI714580B/zh active
- 2016-05-03 CA CA2984696A patent/CA2984696C/en active Active
- 2016-05-03 US US15/571,650 patent/US10479768B2/en active Active
- 2016-05-03 JP JP2017557182A patent/JP6843765B2/ja active Active
- 2016-05-03 ES ES16720114T patent/ES2901788T3/es active Active
- 2016-05-03 HK HK18111639.4A patent/HK1252354A1/zh unknown
- 2016-05-03 PE PE2017002358A patent/PE20181172A1/es unknown
- 2016-05-03 AU AU2016256965A patent/AU2016256965A1/en not_active Abandoned
- 2016-05-03 RU RU2017141979A patent/RU2753541C2/ru active
- 2016-05-03 WO PCT/EP2016/059823 patent/WO2016177693A1/en not_active Ceased
- 2016-05-03 EP EP16720114.4A patent/EP3292106B1/en active Active
- 2016-05-03 CN CN201680039668.4A patent/CN107801395B/zh active Active
- 2016-05-03 PL PL16720114T patent/PL3292106T3/pl unknown
- 2016-05-03 UA UAA201711791A patent/UA123265C2/uk unknown
- 2016-05-04 UY UY0001036667A patent/UY36667A/es not_active Application Discontinuation
- 2016-05-04 AR ARP160101273A patent/AR104524A1/es not_active Application Discontinuation
-
2017
- 2017-10-31 IL IL255344A patent/IL255344B/en active IP Right Grant
- 2017-11-03 CL CL2017002775A patent/CL2017002775A1/es unknown
- 2017-11-03 CO CONC2017/0011326A patent/CO2017011326A2/es unknown
- 2017-11-06 EC ECIEPI201773692A patent/ECSP17073692A/es unknown
- 2017-12-01 ZA ZA2017/08190A patent/ZA201708190B/en unknown
-
2020
- 2020-10-14 AU AU2020256364A patent/AU2020256364B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002742A1 (es) | Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de francisella tularensis; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004) | |
| SG11202108788TA (en) | Methods for processing nucleic acid molecules | |
| BR112013016982A2 (pt) | formas polimórficas de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acético e usos destes | |
| BR112017018728A2 (pt) | sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada | |
| EP2940017A3 (en) | Processes for making compounds useful as inhibitors of atr kinase | |
| MX2015014464A (es) | Vectores para terapia genica para tratar cardiomiopatía. | |
| MX2018003284A (es) | Compuestos antifungicos y procesos para hacerlos. | |
| EP3604524A4 (en) | NEW TECHNOLOGY FOR DIRECT CLONING OF LARGE GENOMIC FRAGMENTS AND DNA MULTIMOLECULAR ARRANGEMENT | |
| BR112017008103A2 (pt) | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. | |
| EP3414255A4 (en) | PREPARATIVE ELECTROPHORETIC PROCESS FOR THE TARGETED CLEANING OF GENOMIC DNA FRAGMENTS | |
| MX354373B (es) | Proceso para hacer compuestos de ciclopentapirimidina hidroxilada y sus sales. | |
| CY1125333T1 (el) | Μεθοδος παρασκευης μιας κρυσταλλικης μορφης της μηλεϊνικης 1-((2r, 4r)-2- (1h-benzo[d] ιμιδαζολ-2- υλο)-1-μεθυλο-πιπεριδιν-4-υλο)-3-(4- κυανοφαινυλ)ουριας· μια κρυσταλλικη μορφη συμπλοκου 1-((2r, 4r)-2- (1h-benzo[d] ιμιδαζολ-2- υλο)-1-μεθυλοπιπεριδιν-4-υλο)-3-(4-κυανοφαινυλ) ουριας ιμιδαζολης (1:1) | |
| CY1117397T1 (el) | Παραγωγα 3-ετεροαρουλαμινο-προπιονικου οξεος και χρηση τους ως φαρμακευτικα | |
| WO2013033407A3 (en) | Identification of small molecules that enhance therapeutic exon skipping | |
| MX2019007137A (es) | Fenilamidinas y su uso como fungicidas. | |
| MX350443B (es) | Proceso para hacer compuestos de aminoácidos. | |
| MX393908B (es) | Proceso mejorado para la preparacion de compuestos anfifilicos de imidazolinio. | |
| IT201900025096A1 (it) | Processo per la sintesi di acido 2,5-furandicarbossilico | |
| JO3712B1 (ar) | طريقة لتحضير 1-(4-ميثان سلفونيل-2-تراي فلورو ميثيل-بنزيل)-2ميثيل-1h-بيرولو[2، 3-b]بيريدين-3-يل-حمض أسيتيك | |
| EP3533450A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ISCHEMIA REPERFUSION DAMAGE WITH BILE ACID | |
| MX2019007111A (es) | Fenoxifenilamidinas y su uso como fungicidas. | |
| JOP20190223A1 (ar) | عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك | |
| IL249428A0 (en) | A polymorphic form of n-[2-(6 fluoro-lh-indol-3-yl)ethyl]-3-(2, 2, 3, 3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's | |
| EP3369417A4 (en) | RNA MOLECULE FOR REPAIRING DNA DAMAGES | |
| EP3411487A4 (en) | GAWKY (GW) NUCLEIC ACID MOLECULES FOR COMBATING INSECT PESTS |